Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Simona Valletta and Dr Sarah Gooding, who were selected for the Translational Research Training in Hematology Program, a year-long training and mentoring experience by the American Society of Hematology and the European Hematology Association.

© Julie Stevens

We are pleased to announce that Dr Simona Valletta (Nerlov group) and Dr Sarah Gooding (Vyas group) at the MRC Molecular Haematology Unit has been selected by the American Society of Hematology (ASH) and the European Hematology Association (EHA) to participate as one of 20 early-career translational researchers in the joint 2020 Translational Research Training in Hematology (TRTH) program.

TRTH is a rigorous year-long training and mentoring experience that helps talented junior scientists build successful careers in translational hematology research. Under the guidance of international leaders, participants work to improve their research project in every sense, including design, adequate statistics, and how to get your work funded. TRTH aims to include participants at a specific stage in career development, namely being a trainee or junior faculty and hold an MD and/or PhD or biomedical PhD or pharmacy PharmD degree (or equivalents).

The TRTH year begins with a week-long Spring Course, designed to give participants a more profound understanding of translational research methodology and career development. Held in France, March 20-27, 2020, the Spring Course includes didactic and interactive sessions and one-on-one faculty mentoring that focuses on refining participants’ research proposals. TRTH participants will convene again at the 25th Congress of EHA in Frankfurt in June, where they will attend small group mentoring sessions. Finally, at the conclusion of the program, participants will present the status of their projects at the 2020 ASH Annual Meeting, December 5-8, in San Diego.

Simona was recently awarded an Intermediate Research Fellowship from the Kay Kendall Leukaemia Fund to study the effects of the ageing bone marrow microevironment in the prognosis of acute myeloid leukaemia (AML). Sarah is an Oxford-Celgene Translational Research Fellow using whole genome sequencing and single cell technologies to understand response and relapse to treatment in myeloma patients.

“This joint program gives scientists from all over the world with an interest in translational research the opportunity to become leaders in the field with the help of mentors,” said 2020 ASH President Stephanie Lee, MD, MPH, of Fred Hutchinson Cancer Research Center. “These talented junior researchers are rising stars in hematology.”

Co-founder of TRTH and EHA President John Gribben, MD, DSc, FRCP, FRCPath, FMedSci, says “We continue the long-term tradition of EHA mentorship for translational scientists and haematologists.  With the help of outstanding faculty members from EHA and ASH we look to ensure that these young stars of the future fulfil their full potential.”

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with


Similar stories

RDM researchers awarded Oxford-Bristol Myers Squibb Fellowships

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Six new Oxford-BMS Fellowships for 2021 were announced.

New atlas revealed of bone marrow haematopoiesis during development

A new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.

Changes in blood cell production over the human lifetime may hold clues to patterns of disease

A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.